Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 + haplo-cord stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Cell Therapies, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This therapeutic protocol involves the sequential administration of CPX-351 (Vyxeos) as salvage chemotherapy followed by a specialized allogeneic stem cell transplantation (SCT) known as a haplo-cord graft. CPX-351 is a liposomal formulation containing cytarabine and daunorubicin in a fixed 5:1 molar ratio, designed to optimize synergistic antileukemic activity while reducing systemic toxicity. The haplo-cord transplant procedure, pioneered at institutions including Weill Medical College of Cornell University, combines CD34-selected hematopoietic progenitor cells from a haploidentical (half-matched) family donor with an umbilical cord blood unit. This dual-graft approach aims to provide rapid initial engraftment from the haploidentical cells while the cord blood unit provides long-term hematopoiesis and a potent graft-versus-leukemia effect. The protocol is primarily investigated for adult patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
- Other names
- CPX-351 followed by haplo-cord SCTCPX351 followed by haplo-cord SCTCPX 351 followed by haplo-cord SCTCPX-351 salvage and haplo-cord transplantCPX351 salvage and haplo-cord transplantCPX 351 salvage and haplo-cord transplanthaplo-cord stem cell transplantation
Beyond the preview
Go deeper on CPX-351 + haplo-cord stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 + haplo-cord stem cell transplantation.